Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer
在 PACE II 期临床试验中,转移性 HR 阳性/HER2 阴性乳腺癌患者接受 CDK4/6 抑制剂治疗后,循环肿瘤 DNA 突变图谱和动态变化
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105506
Jeselsohn, R; Fu, J; Ren, Y; Mahtani, R; Ma, C; DeMichele, A; Cristofanilli, M; Meisel, J; Miller, K D; Abdou, Y; Riley, E C; Qamar, R; Sharma, P; Reid, S; Ko, N; Liu, Y; Gauthier, E; Burstein, H J; DeMeo, M; Regan, M; Tolaney, S M; Mayer, E L